Health

Pharmaceutical startups have had a strong start to 2024, showing off areas like psychedelic mental health treatments, radiotherapeutic cancer drugs and medicine for underserved populations.

Japanese pharma firm Taiho has added $100m to its US-based CVC subsidiary, which has a team of five people.

Bauke Anninga was a principal at M Ventures for two years.

Labour shortages and the ability to accelerate robot programming with genAI will breathe new life into the sector in 2024 say investors.

The ex-Illumina Ventures employee has launched a VC firm where she will be managing partner.

Maersk revamped its Maersk Growth innovation unit in June with a new team and a change in how it invests in tech and sustainability.

Illumina Ventures alumnus Noel Lee has moved up to partner at Novo Holdings, just eight months after being hired as a principal in its Growth Investments team.

Claire Leurent, formerly principal at Johnson & Johnson Innovation – JJDC, has joined AbbVie’s CVC unit as managing director.

Payments is an area fintech investors we've spoken to see as ripe for a shake up. They're also watching for an AI crash and the direction of interest rates.

AI and quantum, as well as long-term, large-scale energy storage are trends at the top of energy investors' minds for 2024. Exits, less so.

The fund, co-managed with a seed-stage VC firm, will target AI, robotics and internet-of-things across multiple industries.